Table 1. The mutational status of 123 patients with BCR-ABL1 rearrangement-negative myeloproliferative neoplasms.
| Mutation | ET, n (%) (n = 74) | PMF, n (%) (n = 4) | PV, n (%)(n = 45) | Total, n (%) | ||||
|---|---|---|---|---|---|---|---|---|
| Mutant | Wild type | Mutant | Wild type | Mutant | Wild type | Mutant | Wild type | |
| JAK2 V617F | 26(35.1) | 48(64.9) | 1(25.0) | 3(75.0) | 19(42.2) | 26(57.8) | 46(37.4) | 77(62.6) |
| JAK2 exon 12 | N/T | N/T | N/T | N/T | 0 | 26 | 0 | 26 |
| MPL exon 10 | 1(2.1) | 47(97.9) | 2(66.7) | 1(33.3) | N/T | N/T | 3(5.9) | 48(94.1) |
| CALR exon 9 | 23*(31.1) | 51(68.9) | 1(25.0) | 3(75.0) | 1*(2.2) | 44(97.8) | 25(20.3) | 98(79.7) |
ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera; CNL, chronic neutrophilic leukemia; n, number; N/T, not tested.
*
Two patients with ET and 1 patient with PV had a low mutant allele burden; therefore, mutations were detected via fragment analysis rather than direct sequencing. Those cases were considered to be mutated.